C4 Therapeutics (CCCC) Free Cash Flow (2019 - 2026)

C4 Therapeutics' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$30.0 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 9.92% year-over-year to -$30.0 million in Q1 2026; TTM through Mar 2026 was -$96.0 million, a 19.25% decrease from a year earlier, with the FY2025 full-year figure at -$99.3 million, down 51.98% from the prior year.
• Free Cash Flow slipped to -$30.0 million in Q1 2026 per CCCC's latest filing, from -$22.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$5.0 million in Q2 2024 and bottomed at -$33.7 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$24.3 million (2024), against an average of -$24.4 million.
• Across the five-year window, Free Cash Flow jumped 74.24% in 2024 and sank 145.48% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$30.6 million in 2022, then climbed by 21.07% to -$24.2 million in 2023, then gained by 25.81% to -$17.9 million in 2024, then declined by 26.77% to -$22.7 million in 2025, then slumped by 31.92% to -$30.0 million in 2026.
• Per Business Quant, the three latest CCCC Free Cash Flow figures stand at -$30.0 million (Q1 2026), -$22.7 million (Q4 2025), and -$31.0 million (Q3 2025).